Cryo-Cell Intl Inc (CCEL) 4.0000 $CCEL
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against Cryo-Cell International, Inc. and Advises Investors to Contact the Firm
BusinessWire - Tue Jul 19, 6:00AM CDT
Khang & Khang LLP announces that it is investigating claims against Cryo-Cell International, Inc. ("Cryo-Cell" or the "Company"

(OTC MKTS: CCEL). The investigation focuses on whether the Company and its officers violated Delaware law.
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 14, 4:00PM CDT
Cryo-Cell International, Inc. (OTCQB:CCEL) (the "Company"

, the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2016.
Cryo-Cell Reports Fiscal Third Quarter 2015 Results
GlobeNewswire - Fri Oct 16, 4:00PM CDT
Cryo-Cell International, Inc. (the "Company"

(OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2015.
Cryo-Cell, Cord Blood Banking Company, Announces Final Results of Its Tender Offer
GlobeNewswire - Thu Jul 30, 12:00PM CDT
Cryo-Cell International, Inc. (the "Company"

(OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced today final results of its tender offer to purchase up to 750,000 shares of its common stock at a price of $3.25 per share, which expired at 12:00 midnight, New York City time on Tuesday, July 28, 2015.
Cryo-Cell Reports Fiscal First Quarter 2015 Financial Results
GlobeNewswire - Thu Jul 16, 3:00PM CDT
Cryo-Cell International, Inc. (the "Company"

(OTCQB:CCEL), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the second fiscal quarter ended May 31, 2015.
Cryo-Cell Adopts Three-Year Stockholder Rights Plan
GlobeNewswire - Wed Dec 03, 5:30PM CST
Cryo-Cell International, Inc. (OTCQB:CCEL) ("Cryo-Cell" or the "Company"

, the world's first company to offer cord blood banking services, announced today that its Board of Directors (the "Board"

has unanimously adopted a three-year stockholder rights plan (the "Plan"

, effective December 5, 2014, and declared a dividend distribution of one preferred share purchase right on each outstanding share of the Company's common stock, as well as certain other shares that become outstanding, such as upon the exercise of stock options or conversion or exchange of securities or notes.